Inspiremd Stock Performance
| NSPR Stock | USD 1.65 0.03 1.85% |
The company retains a Market Volatility (i.e., Beta) of 1.51, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, InspireMD will likely underperform. At this point, InspireMD has a negative expected return of -0.41%. Please make sure to check out InspireMD's maximum drawdown, daily balance of power, as well as the relationship between the Daily Balance Of Power and period momentum indicator , to decide if InspireMD performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days InspireMD has generated negative risk-adjusted returns adding no value to investors with long positions. Even with weak performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in February 2026. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors. ...more
Last Split Factor 1:15 | Dividend Date 2019-04-01 | Last Split Date 2021-04-27 |
1 | InspireMD Inc Q3 2025 Earnings Call Highlights Robust Revenue Growth Amid Rising Expenses | 11/04/2025 |
2 | Is InspireMD Inc. stock poised for growth - Portfolio Risk Report Fast Exit and Entry Trade Guides - newser.com | 11/17/2025 |
3 | InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635 | 11/21/2025 |
4 | Landmark CREST-2 Study Published in the New England Journal of Medicine Highlights the Benefits of Carotid Artery Stenting | 11/24/2025 |
5 | Acquisition by Stuka Paul of 10130 shares of InspireMD at 1.85 subject to Rule 16b-3 | 12/04/2025 |
6 | Acquisition by Stuka Paul of 5073 shares of InspireMD at 1.81 subject to Rule 16b-3 | 12/09/2025 |
7 | Acquisition by Arnold Kathryn of 26276 shares of InspireMD at 1.89 subject to Rule 16b-3 | 12/30/2025 |
8 | InspireMD Announces Publication of the C-GUARDIANS Pivotal Trial Manuscript in the Journal of the American College of Cardiology | 01/12/2026 |
9 | Acquisition by Berman Michael of 88053 shares of InspireMD subject to Rule 16b-3 | 01/14/2026 |
| Begin Period Cash Flow | 9.6 M | |
| Total Cashflows From Investing Activities | 12.6 M | |
| Free Cash Flow | -23.3 M |
InspireMD | Build AI portfolio with InspireMD Stock |
InspireMD Relative Risk vs. Return Landscape
If you would invest 227.00 in InspireMD on October 29, 2025 and sell it today you would lose (62.00) from holding InspireMD or give up 27.31% of portfolio value over 90 days. InspireMD is currently does not generate positive expected returns and assumes 4.7482% risk (volatility on return distribution) over the 90 days horizon. In different words, 42% of stocks are less volatile than InspireMD, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
InspireMD Target Price Odds to finish over Current Price
The tendency of InspireMD Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 1.65 | 90 days | 1.65 | about 91.15 |
Based on a normal probability distribution, the odds of InspireMD to move above the current price in 90 days from now is about 91.15 (This InspireMD probability density function shows the probability of InspireMD Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days the stock has the beta coefficient of 1.51 . This indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, InspireMD will likely underperform. Additionally InspireMD has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. InspireMD Price Density |
| Price |
Predictive Modules for InspireMD
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as InspireMD. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.InspireMD Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. InspireMD is not an exception. The market had few large corrections towards the InspireMD's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold InspireMD, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of InspireMD within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.55 | |
β | Beta against Dow Jones | 1.51 | |
σ | Overall volatility | 0.20 | |
Ir | Information ratio | -0.11 |
InspireMD Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of InspireMD for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for InspireMD can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| InspireMD generated a negative expected return over the last 90 days | |
| InspireMD may become a speculative penny stock | |
| InspireMD has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 7.01 M. Net Loss for the year was (32.01 M) with profit before overhead, payroll, taxes, and interest of 1.94 M. | |
| InspireMD currently holds about 26.47 M in cash with (21.87 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.18, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| InspireMD has a frail financial position based on the latest SEC disclosures | |
| Roughly 55.0% of the company shares are owned by institutional investors | |
| Latest headline from globenewswire.com: InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635 |
InspireMD Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of InspireMD Stock often depends not only on the future outlook of the current and potential InspireMD's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. InspireMD's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 41.9 M | |
| Cash And Short Term Investments | 34.6 M |
InspireMD Fundamentals Growth
InspireMD Stock prices reflect investors' perceptions of the future prospects and financial health of InspireMD, and InspireMD fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on InspireMD Stock performance.
| Return On Equity | -0.88 | ||||
| Return On Asset | -0.45 | ||||
| Operating Margin | (5.17) % | ||||
| Current Valuation | 8.61 M | ||||
| Shares Outstanding | 42.37 M | ||||
| Price To Earning | (0.16) X | ||||
| Price To Book | 1.07 X | ||||
| Price To Sales | 8.99 X | ||||
| Revenue | 7.01 M | ||||
| Gross Profit | 1.94 M | ||||
| EBITDA | (33.22 M) | ||||
| Net Income | (32.01 M) | ||||
| Cash And Equivalents | 26.47 M | ||||
| Cash Per Share | 3.18 X | ||||
| Total Debt | 2.34 M | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 6.26 X | ||||
| Book Value Per Share | 1.53 X | ||||
| Cash Flow From Operations | (21.87 M) | ||||
| Earnings Per Share | (0.82) X | ||||
| Market Capitalization | 69.91 M | ||||
| Total Asset | 46.81 M | ||||
| Retained Earnings | (253.51 M) | ||||
| Working Capital | 32.84 M | ||||
| Current Asset | 4.63 M | ||||
| Current Liabilities | 6.83 M | ||||
About InspireMD Performance
Assessing InspireMD's fundamental ratios provides investors with valuable insights into InspireMD's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the InspireMD is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 196.03 | 198.00 | |
| Return On Tangible Assets | (0.62) | (0.65) | |
| Return On Capital Employed | (0.98) | (0.94) | |
| Return On Assets | (0.62) | (0.65) | |
| Return On Equity | (1.02) | (0.97) |
Things to note about InspireMD performance evaluation
Checking the ongoing alerts about InspireMD for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for InspireMD help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| InspireMD generated a negative expected return over the last 90 days | |
| InspireMD may become a speculative penny stock | |
| InspireMD has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 7.01 M. Net Loss for the year was (32.01 M) with profit before overhead, payroll, taxes, and interest of 1.94 M. | |
| InspireMD currently holds about 26.47 M in cash with (21.87 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.18, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| InspireMD has a frail financial position based on the latest SEC disclosures | |
| Roughly 55.0% of the company shares are owned by institutional investors | |
| Latest headline from globenewswire.com: InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635 |
- Analyzing InspireMD's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether InspireMD's stock is overvalued or undervalued compared to its peers.
- Examining InspireMD's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating InspireMD's management team can have a significant impact on its success or failure. Reviewing the track record and experience of InspireMD's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of InspireMD's stock. These opinions can provide insight into InspireMD's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for InspireMD Stock Analysis
When running InspireMD's price analysis, check to measure InspireMD's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy InspireMD is operating at the current time. Most of InspireMD's value examination focuses on studying past and present price action to predict the probability of InspireMD's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move InspireMD's price. Additionally, you may evaluate how the addition of InspireMD to your portfolios can decrease your overall portfolio volatility.